Gilead Sciences (GILD) Shares Outstanding (2009 - 2026)
Gilead Sciences' (GILD) quarterly Shares Outstanding (Entity) came in at $1.2 billion in Q1 2026, little changed YoY from $1.2 billion in Q1 2025, and little changed on a QoQ basis from $1.2 billion in Q4 2025.
Gilead Sciences (GILD) Shares Outstanding (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Shares Outstanding (Entity) data on file, last reported at $1.2 billion in Q1 2026.
- Quarterly Shares Outstanding (Entity) changed 0.24% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (changed 0.24% YoY) and the FY2025 annual result came in at $1.2 billion, changed 0.4% from the prior year.
- Shares Outstanding (Entity) held at $1.2 billion in Q1 2026, from $1.2 billion in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $1.3 billion in Q1 2022 to a low of $1.2 billion in Q4 2025.
- A 5-year average of $1.2 billion and a median of $1.2 billion in 2023 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 0.08% in 2022, down 0.56% in 2022.
- Tracing GILD's Shares Outstanding (Entity) over 5 years: stood at $1.2 billion in 2022, then dropped by 0.08% to $1.2 billion in 2023, then changed by 0.0% to $1.2 billion in 2024, then retreated by 0.4% to $1.2 billion in 2025, then rose by 0.08% to $1.2 billion in 2026.
- The last three Shares Outstanding (Entity) figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 Bn |
| Mar 31, 2026 | 1.24 Bn |
| Dec 31, 2025 | 1.24 Bn |
| Sep 30, 2025 | 1.24 Bn |
| Jun 30, 2025 | 1.25 Bn |
| Mar 31, 2025 | 1.25 Bn |
| Dec 31, 2024 | 1.25 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.25 Bn |
| Dec 31, 2023 | 1.25 Bn |
| Sep 30, 2023 | 1.25 Bn |
| Jun 30, 2023 | 1.25 Bn |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 1.26 Bn |
| Sep 30, 2022 | 1.26 Bn |
| Jun 30, 2022 | 1.26 Bn |
| Mar 31, 2022 | 1.26 Bn |
| Dec 31, 2021 | 1.26 Bn |
| Sep 30, 2021 | 1.26 Bn |